ClinicalTrials.govpublic full text
Consolidation Sintilimab After Concurrent Chemoradiation in Patients With Unresectable Stage III NSCLC
carcinoma, non-small cell lung, locally advanced, stage iii non-small cell lung cancer, unresectable non-small cell lung cancer, concurrent chemoradiation, immune-mediated cancer therapy, pd-1, sintilimab, ibi308, interventional, phase3
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 806483
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.